Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

ABSTRACT The majority of hospitalized patients receiving mold-active triazoles are at risk of drug-drug interactions (DDIs). Efforts are needed to increase awareness of DDIs that pose a serious risk of adverse events. Triazoles remain the most commonly utilized antifungals. Recent developments have included the mold-active triazoles (MATs) itraconazole, voriconazole, and posaconazole, which are first-line agents for the treatment of filamentous fungal infections but have the potential for DDIs. This objective of this study was to evaluate the prevalence of triazole DDIs. Hospitalized U.S. adults with MAT use were identified in the Cerner HealthFacts database, which contained data from over 150 hospitals (2005 to 2013). The severities of DDIs with MATs were categorized, using drug labels and the drug information from the Drugdex system (Thompson Micromedex), into four groups (contraindicated, major, moderate, and minor severity). DDIs of minor severity were not counted. A DDI event was considered to have occurred if the following two conditions were met: (i) the patient used at least one drug with a classification of at least a moderate interaction with the MAT during the hospitalization and (ii) there was a period of overlap between the administration of the MAT and that of the interacting drug of at least 1 day. A total of 6,962 hospitalizations with MAT use were identified. Among them, 88% of hospitalizations with voriconazole use, 86% of hospitalizations with itraconazole use, and 93% of hospitalizations with posaconazole use included the use of a concomitant interacting drug. A total of 68% of hospitalizations with posaconazole use, 34% of hospitalizations with itraconazole use, and 20% of hospitalizations with voriconazole use included the use of at least one drug with a DDI of contraindicated severity. A total of 83% of hospitalizations with posaconazole use, 61% of hospitalizations with itraconazole use, and 82% of hospitalizations with voriconazole use included the use of at least one drug that resulted in a severe DDI. The findings of this study demonstrate that a majority of hospitalized patients receiving MAT are at risk for severe drug-drug interactions and highlight the need for antifungal stewardship.

[1]  John W. Wilson,et al.  Effect of Combined Fluoroquinolone and Azole Use on QT Prolongation in Hematology Patients , 2012, Antimicrobial Agents and Chemotherapy.

[2]  D. Horn,et al.  The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. , 2012, Diagnostic microbiology and infectious disease.

[3]  R. Schlienger,et al.  Potential drug–drug interactions in the medication of medical patients at hospital discharge , 2003, European Journal of Clinical Pharmacology.

[4]  J. Pergolizzi,et al.  Economic Impact of Potential CYP450 Pharmacokinetic Drug–Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids , 2012, Pain practice : the official journal of World Institute of Pain.

[5]  E. Bernasconi,et al.  Assessment of potential drug-drug interactions at hospital discharge. , 2010, Swiss medical weekly.

[6]  S. Lubinga,et al.  Potential drug-drug interactions on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors. , 2011, African health sciences.

[7]  J. Perfect,et al.  Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. , 2008, The Journal of antimicrobial chemotherapy.

[8]  E. Çiftçi,et al.  Voriconazole‐induced QT interval prolongation and torsades de pointes , 2011, Pediatrics international : official journal of the Japan Pediatric Society.

[9]  D. Andes.  Optimizing antifungal choice and administration , 2013, Current medical research and opinion.

[10]  Felix Hammann,et al.  Data mining for potential adverse drug–drug interactions , 2014, Expert opinion on drug metabolism & toxicology.

[11]  J. Perfect,et al.  Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  G. Ubeaud‐Séquier,et al.  Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. , 2009, Current drug metabolism.

[13]  Yusuke Tanigawara,et al.  MICROMEDEX® Healthcare Series , 2004 .

[14]  David W Bates,et al.  Frequency of potential azole drug–drug interactions and consequences of potential fluconazole drug interactions , 2005, Pharmacoepidemiology and drug safety.

[15]  P. Gubbins,et al.  Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450 , 2011, Expert opinion on drug metabolism & toxicology.

[16]  D. Loebenberg,et al.  Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. , 2005, The Journal of antimicrobial chemotherapy.

[17]  G. Thompson,et al.  Update on the optimal use of voriconazole for invasive fungal infections , 2011, Infection and drug resistance.

[18]  R. Lewis.  Current concepts in antifungal pharmacology. , 2011, Mayo Clinic proceedings.

[19]  H. Brenner,et al.  Drug interactions in primary care: Impact of a new algorithm on risk determination , 2004, Clinical pharmacology and therapeutics.

[20]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[21]  J. Kosterink,et al.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  W. Haefeli,et al.  Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  E. Dodds-Ashley.  Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients , 2010, Pharmacotherapy.

[24]  R. Ohsfeldt,et al.  Economic impact of potential drug–drug interactions in opioid analgesics , 2011, Journal of medical economics.

[25]  Albert P. Li,et al.  The Scientific Basis of Drug-Drug Interactions: Mechanism and Preclinical Evaluation , 1998 .

[26]  Jason C. Gallagher,et al.  Antifungal pharmacotherapy for invasive mould infections , 2003, Expert opinion on pharmacotherapy.

[27]  Varsha J. Patel,et al.  A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital , 2014, Journal of basic and clinical pharmacy.